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Abstract
Hepatic ischemia-reperfusion injury (IRI) limits access 
to transplantation. Heme oxygenase-1 (HO-1) is a pow-
erful antioxidant enzyme which degrades free heme into 
biliverdin, free iron and carbon monoxide. HO-1 and its 
metabolites have the ability to modulate a wide variety 
of inflammatory disorders including hepatic IRI. Mecha-
nisms of this protective effect include reduction of oxy-
gen free radicals, alteration of macrophage and T cell 
phenotype. Further work is required to understand the 
physiological importance of the many actions of HO-1 
identified experimentally, and to harness the protective 
effect of HO-1 for therapeutic potential.
© 2010 Baishideng. All rights reserved.
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THE CLINICAL IMPACT OF HEPATIC 
ISCHEMIA-REPERFUSION INJURY
The rate of  liver failure is increasing in the UK popula-
tion[1]. Liver transplantation is an effective treatment for 
patients with end-stage disease, giving an average of  17-22 
years of  additional life[2,3]. Access to liver transplantation is 
limited by donor availability; several innovations, including 
split liver, living donor transplantation, non-heart beating 
donation (NHBD) and the expansion of  the donor crite-
ria, have been attempted to tackle this disparity[4]. 
Ischemia-reperfusion injury (IRI) causes a spectrum 
of  early organ dysfunction after transplantation; the most 
severe form, termed primary non-function, may result in 
patient death. “Marginal organs”, including those from 
older donors, those affected by steatosis and those from 
donors with long pre-donation intensive care unit stay, 
may be judged to pose an excessive risk of  IRI and be dis-
carded, placing additional pressure on the already scarce 
donor resource[5].
Due to shifting patterns of  organ donation, there is a 
tendency towards the increased use of  marginal organs. 
Year on year, the mean donor age is increasing, in part due 
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to improvements in road safety and declining numbers 
of  traumatic deaths. Furthermore, NHBD (also termed 
donation after cardiac death) is becoming an increasingly 
important component of  the donor resource[6]. Compared 
with the “gold standard” of  heart beating donation (HBD), 
NHBD is associated with a decreased quantity of  donated 
organs (2.1 organs per donor compared with 3.4 organs 
per HBD). Albeit in small studies, NHBD liver transplan-
tation is also associated with a higher risk of  IRI leading 
to elevated incidence of  primary non-function[7].
Our group has previously estimated that negating the 
effects of  IRI in HBD would lead to a 6% increase in the 
donor supply through recruitment of  these marginal or-
gans back into the donor pool[4]. In the current climate of  
rapidly increasing NHBD and increasing donor age, the 
imperative to better understand and avert hepatic ischemia 
is becoming ever stronger. 
DEFINITION OF IRI
Interruption of  blood flow to any tissue results in inad-
equate tissue oxygenation and an increase in cellular an-
aerobic pathways: if  adequate oxygenation is not restored 
then disruption of  cellular functions and cell death results. 
On reperfusion, despite restoration of  adequate cellular 
oxygenation, there is further damage caused both by direct 
cytotoxicity from oxygen free radicals (OFR)[8] and by a 
secondary immunological assault upon the injured organ 
involving components of  both the innate and adaptive im-
mune system[9]. The sequence of  injuries resulting from in-
terruption then reinstatement of  blood flow is termed IRI. 
HEME OXYGENASE-1
Heme oxygenase (HO) is a nicotinamide adenine di-
nucleotide phosphate (NADPH)-dependent microsomal 
enzyme, which catalyzes the breakdown of  heme to bili-
verdin, iron and carbon monoxide (CO)[10] (Figure 1). Bili-
verdin is subsequently reduced to bilirubin by biliverdin 
reductase while free iron is sequestrated by ferritin. Of  the 
three heme oxygenase isoforms (HO-1, HO-2 and HO-3), 
only HO-1 (also known as heat shock protein 32) is induc-
ible[11]. HO-1 is a 32 kDa enzyme encoded by the hmox1 
gene. It has been found to be upregulated during states of  
oxidative and cellular stress and plays an important role in 
maintaining oxidative/antioxidant homeostasis[12]. 
Induction of  HO-1 and its metabolites is protective 
in a large number of  seemingly unrelated pathologies, 
including sepsis, malaria, endotoxic shock, IRI, organ 
transplant rejection, induction of  tolerance, myocardial 
infarction, type 2 diabetes and obesity[13]. This spectrum 
of  protection is attributed to multi-level mechanisms of  
cytoprotection and inflammatory modulation. 
Polymorphism in the (GT)n microsatellite of  the 
HMOX1 promoter is thought to be responsible for the vari-
ations seen in the human response of  HO-1 to stimuli[14]. 
This may account for the differences in the susceptibility 
of  individuals to certain pathologies and in the apparent 
longevity associated with increased HO-1 expression[15,16].
HO-1 in hepatic IRI
In the context of  IRI and transplantation, HO-1 induc-
tion or supplementation with its metabolites has been 
shown repeatedly to be protective in both the liver and 
other organs. 
In early experiments, HO-1 was induced by heat shock 
in donor livers prior to 44 h of  cold ischemia preceding 
liver isogeneic transplantation in rats, resulting in marked 
improvements in recipient survival[17]. HO-1 upregulation 
with adenoviral HO-1 or cobalt protoporphyrin (CoPP) re-
sulted in improved portal venous flow on ex-vivo perfusion, 
while on transplantation into syngeneic hosts, recipient 
survival doubled, histological injury was ameliorated and 
influx of  macrophages and T cells was reduced[18]; findings 
confirmed in similar experiments using transplantation[19,20] 
and hepatic warm ischemia models[21]. More recently, tar-
geted deletion of  Bach-1, which normally suppresses HO-1 
transcription, led to HO-1 upregulation and protection 
from myocardial ischemia[22], although these experiments 
have yet to be repeated in models of  hepatic ischemia. 
In our own laboratory we have shown that HO-1 is 
upregulated in Kupffer cells during ischemic precondition-
ing (IPC)[23], and that targeted deletion of  hmox-1 resulted 
in aberrant Kupffer cell differentiation and susceptibility 
to ischemia-reperfusion insults[24]. Our work has suggested 
that Kupffer cells are a likely site of  HO-1 action: recent 
work from Kupiec Weglinski’s laboratory has demonstrat-
ed that adoptive transfer of  HO-1 overexpressing bone 
marrow-derived macrophages was capable of  protecting 
mice from hepatic ischemic insults[25]. Developing this 
theme, other experiments have shown HO-1 induction 
with CoPP to protect mice from hepatic ischemia arising 
from liver transplantation: Kupffer cells recovered from 
HO-1-induced animals produced less tumor necrosis fac-
tor α (TNFα) and interleukin (IL)-6 under stimulation in 
ex vivo culture[26]. 
HO-1 in hepatic IPC
IPC is a surgical maneuvre in which an organ is paradoxi-
cally protected by a brief  period of  controlled ischemia 
and reperfusion immediately prior to a longer index 
ischemic event, which by itself  would normally lead to 
injury[27,28]. Several small randomized controlled trials have 
looked at the effectiveness of  IPC in both liver transplan-
tation and resection; subsequent Cochrane reviews con-
clude that further trials are still required to evaluate its role 
in hepatic and transplant surgery[29,30]. 
Kanoria et al[31] demonstrated in their rodent model 
that the application of  a hindleg tourniquet (remote IPC) 
led to a protective phenotype from hepatic IRI. Ischemic 
post-conditioning has also been described, in which injury 
is abrogated by modified reperfusion. This emphasizes 
that tissue damage from ischemia-reperfusion continues 
following the end of  the ischemic insult[32].
The mechanisms behind IPC are poorly understood. 
Numerous candidate molecules, including nitric oxide, 
adenosine, protein kinase C, tyrosine kinase and mitogen-
activated-protein kinase, have been identified as potential 
mediators of  protection[33]. Given that IPC can act re-
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motely, it may involve an immunomodulatory mechanism. 
HO-1 is upregulated following IPC and may be re-
sponsible for the observed protection[23]. HO-1 is also up-
regulated in sites distant to the site of  preconditioning. In 
a remote preconditioning model, renal ischemic insults led 
to cardiac HO-1 induction[34]. Likewise, HO-1 induction 
occurred in the liver following four 10 min episodes of  
femoral artery occlusion, and protection afforded by re-
mote preconditioning was lost when HO-1 was inhibited 
with SnPP[35].
Given that HO-1 is upregulated in IPC and is known 
to be powerfully protective when upregulated, it is likely 
that HO-1 has a role in IPC together with other up- and 
downstream molecules.
Mechanisms of HO-1-mediated cytoprotection
As described above, it is now beyond doubt that HO-1 
induction is protective in the context of  hepatic ischemia 
and transplantation. HO-1’s cytoprotective effects can be 
credited to a combination of  removal of  toxic metabolites 
(heme), and production of  protective second messenger 
molecules in the forms of  biliverdin (and subsequently 
bilirubin), CO, and free iron (which induces ferritin)[36]. 
HO-1 may also have other mechanisms of  protection, in-
dependent of  its enzyme activity[37].
Catabolysis of free heme 
Heme consists of  an iron atom contained within a por-
phyrin ring: heme moieties are usually contained within 
the “heme pockets” of  hemoproteins. Although the most 
abundant hemoproteins are hemoglobin and myoglobin, 
heme moieties are contained within many other ubiqui-
tous enzymes, for example iNOS and the mitochondrial 
electron transfer chain. 
Under conditions of  oxidative stress, hemoproteins 
may be oxidized, leading to the release of  free heme which 
causes cellular injury by multiple mechanisms. Firstly, the 
central iron ion of  the heme moiety catalyzes the produc-
tion of  free radicals by Fenton chemistry as follows: Step 1: 
Fe2+ + H2O2 → Fe3+ + OH· + OH-; Step 2: Fe3+ + H2O2 
→ Fe2+ + OOH· + H+. 
Heme-dependent free radical generation can cause 
direct cytotoxicity, including damage to the cytoskel-
eton, lipid bilayer, intermediary metabolic enzymes and 
DNA[38,39], while circulating heme can cause LDL oxida-
tion leading to endothelial cell toxicity[40]. Heme sensitizes 
cells to pro-death signals including TNFα and Fas, an 
effect abrogated by treatment with antioxidants, implying 
dependence upon free radical production[36]. 
HO-1 reduces free heme concentrations by two mech-
anisms. Firstly, catabolysis of  heme into metabolites bili-
verdin, iron and CO directly removes free heme. Secondly, 
binding of  CO to hemoglobin, forming carboxyhemoglo-
bin, prevents its oxidation to methemoglobin and ensuing 
release of  free heme moieties[36]. 
Some authors have argued strongly that neutraliza-
tion of  free heme during cellular injury can account for a 
large proportion of  the protection offered by HO-1. In 
experimental malaria, it was found that C57/Bl6J mice 
had reduced HO-1 induction compared with BALB/c 
animals, and consequently had higher levels of  circulating 
free heme and greater disease severity. Administering ex-
ogenous heme to BALB/c animals caused worsening of  
their disease severity whereas conversely, CO treatment of  
C57Bl6J mice was protective[41]. In the same model, HO-1 
protected animals from hepatic failure induced by over-
whelming circulating heme[42]. 
Hepatic HO-1 expression is focused in Kupffer cells. 
This cell type is highly adapted to detect hemolysis: the 
hemoglobin-haptoglobin complex receptor CD163 is able 
to induce HO-1 in an IL-10-dependent manner[43,44]. 
Production of biliverdin
Biliverdin is produced by catalysis of  the heme porphyrin 
ring and is almost immediately converted by biliverdin 
reductase to unconjugated bilirubin. This, in turn, is gluc-
uronidated to render it water soluble. Bilirubin is a pow-
erful antioxidant believed to be responsible for much of  
the antioxidant activity of  serum[45]. At micromolar con-
centrations it is capable of  scavenging large volumes of  
reactive oxygen species (ROS), protecting cells from high 
concentrations of  peroxide, with enhanced efficacy in 
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Figure 1  Putative mechanisms of heme oxygenase-1 antioxidant effect. HO-1: Heme oxygenase-1; BVR: Biliverdin; OFR: Oxygen free radicals; NADPH: Nicotin-
amide adenine dinucleotide phosphate.
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hypoxic conditions, making this effect particularly relevant 
in the context of  ischemia[46]. Bilirubin’s extraordinary an-
tioxidant capacity may arise from an active cycle in which 
biliverdin reductase undertakes NADPH-dependent 
reduction of  biliverdin to bilirubin: in turn bilirubin is oxi-
dized by free radicals back to biliverdin, before enzymatic 
reduction back to bilirubin. Although controversial[47], this 
cycling mechanism has been proposed as a highly adapted 
mechanism through which cells and whole organisms 
maintain redox status[45]. 
Bilirubin’s effects may extend beyond its antioxidant 
action. It has been identified as an endogenous ligand of  
the aryl hydrocarbon receptor (AHR), present on many 
immune cell populations[48]. In some experiments AHR li-
gands have suppressed T cell proliferation through expan-
sion of  T regulatory (Treg) cells[49], although expansion of  
either Treg or their polar opposite, Th17 cells, has been 
shown depending upon which experimental AHR ligand 
is used[50]. 
Patients with persistent hyperbilirubinemia (Gilbert’s 
syndrome) have been observed to have significantly lower 
incidence of  atherosclerotic disease in several studies, an 
effect attributed to enhanced antioxidant potential of  se-
rum[51]. The effect of  chronic hyperbilirubinemia upon T 
cell phenotype is unclear, although immunosuppression 
has been reported in patients with cholestatic jaundice[52]. 
Work using ex vivo liver perfusion models in which 
explanted livers were stored for 16[53] or 24 h[54] at 4℃ in 
University of  Wisconsin solution, prior to mechanical 
perfusion, found that addition of  low concentrations of  
bilirubin to the graft perfusate mimicked the protective 
effect of  heme oxygenase induction. Graft function was 
improved in terms of  portal venous flow and bile produc-
tion, and hepatocellular injury was ameliorated in terms 
of  histological injury scoring and transaminase release. 
Biliverdin has also been shown to have an immunomodu-
latory effect. In an MHC-mismatched cardiac allograft 
model, twice or three times daily injections of  biliverdin 
for 2 wk increased graft survival, and led to complete al-
lograft tolerance in 50% of  animals[55].
To test whether bilirubin was protective in the clinical 
setting, our group hypothesized that hyperbilirubinemia 
would protect transplant recipients from IRI, in which 
case there would be an inverse correlation between pre-
operative bilirubin and post-operative transaminase mea-
surements. In a small retrospective study, no relationship 
was observed, although given the heterogeneity of  the 
study population an effect could not be ruled out[56].
Production of Fe2+
Paradoxically for an antioxidant enzyme, one of  HO-1’s 
reaction products, free iron, is a powerful oxidant. Free 
iron catalyzes the generation of  OFR by Fenton chemistry 
in a manner comparable to free heme as described above. 
However, it is more effectively neutralized than when con-
tained within a heme ring, being actively exported from 
the cell[57] and chelated by iron-binding proteins, including 
ferritin. Ferritin sequesters Fe2+ by oxidation and place-
ment of  iron ions within a “core” in which they are un-
able to catalyze Fenton reactions[58]. HO-1 induction leads 
to increased ferritin expression[59], through a mechanism 
dependent upon the production of  free iron[60,61]. 
Since other HO-1 metabolites had been shown to be 
capable of  substituting for HO-1 induction in protecting 
animals from IRI, Berberat et al[62] hypothesized that ferri-
tin overexpression could also confer protection. Using an 
ex vivo perfusion model of  hepatic IRI, this group identi-
fied that transfection with adenoviral heavy chain ferritin 
conferred protection in terms of  bile flow, portal blood 
flow, histological injury scoring and transaminase release, 
and improved survival of  syngeneic liver recipients. 
Ferritin induction has been observed in retinal[63] and 
cardiac IPC[64] in a manner dependent upon an iron sig-
nal[65]: although there are no published studies of  ferritin 
expression in hepatic preconditioning, it would be reason-
able to hypothesize that similar results would be obtained. 
Although ferritin is capable of  protecting cells and 
organs from oxidative stress, it is worth noting that its 
induction is unlikely to be the only mechanism of  cellular 
protection by HO-1. Sheftel et al[61] compared heme and 
sodium arsenite (a non-heme inducer of  HO-1) in vitro, 
and found sodium arsenite to confer protection through 
HO-1 induction without parallel ferritin induction. 
Production of CO
CO is best known for its toxicity, causing death at atmo-
spheric concentrations of  500-1000 ppm, however, at low-
er doses CO has been shown to have important cytopro-
tective and immunomodulatory functions: it is released by 
HO-1 during the catabolysis of  heme and can substitute 
for the protective effect of  HO-1. 
CO cannot have a specific receptor since it binds only 
to transition metals and is not thought to be capable of  
direct interaction with amino acids. Therefore, its phar-
macology as a signaling molecule is necessarily novel, and 
subject to ongoing debate. An important hypothesis is 
that CO effects must be mediated by interactions with 
proteins which contain transition metal cores, for example 
in heme rings contained within a range of  enzymes in-
cluding soluble guanylate cyclase (sGC), cytochromes, 
hemoglobin, myoglobin and nitric oxide synthase[66]. It has 
been suggested that CO protects from oxidative stress by 
preventing hemoprotein oxidation and subsequent release 
of  heme rings[36], diminishing production of  free radi-
cals and subsequent apoptosis[67]. Others have suggested 
that the protection may be mediated by antagonism of  
respiratory chain enzymes, reducing cellular oxygen re-
quirements[66], by inducing vasodilatation via sGC[68] or by 
opening calcium-sensitive ion channels[69].
Using an ex-vivo liver perfusion model, Amersi et al[70] 
demonstrated enhanced portal blood flow and bile pro-
duction, and amelioration of  hepatic IRI, in terms of  
histological injury score and transaminase release when 
perfusate was supplemented with CO at 300 ppm. Block-
ade of  heme oxygenase using zinc protoporphyrin (ZnPP) 
did not obliterate the protective effect, indicating that CO 
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was capable of  substituting for HO-1 function. Inhibitor 
studies have demonstrated that the CO effect was inde-
pendent of  iNOS and cGMP but dependent upon p38 
MAPK.
In a cardiac transplantation model, no hearts stored at 
4℃ for 24 h prior to implantation into syngeneic recipients 
functioned after implantation, whereas 5 out of  6 grafts 
survived when HO-1 was induced with CoPP, an effect 
lost with HO-1 inhibition. Administration of  400 ppm 
CO to the heart donor during cold storage resulted in sur-
vival equivalent to that achieved with HO-1 induction[71]. 
In xenotransplant models, HO-1 inhibition with tin proto-
porphyrin (SnPP) caused rejection, whereas this effect was 
overcome by recipient CO inhalation[72].
Although the finding that CO can be protective at low 
doses is scientifically exciting, the potential therapeutic 
use of  inhaled CO can be limited by practical difficulties, 
both in control of  dosage, and spillage of  the gas into the 
environment around the patient. For this reason, Motter-
lini has developed transition metal carbonyl “CO releasing 
compounds” (CORMs). Of  these (CORM-A1, CORM-2, 
CORM-3), the most commonly used has been CORM-3 
[tricarbonylchloro(glycinato)ruthenium(II)], which releases 
CO when dissolved in saline but not water[73]. To control 
for the presence of  the ruthenium compound, a CO de-
pleted substance (iCORM3) can be prepared by dissolving 
CORM-3 in PBS prior to the experiment. 
Using a coronary occlusion model in which mice were 
subjected to 30 min of  ischemia followed by 24 h of  re-
perfusion, investigators administered CORM-3 during the 
first hour of  reperfusion, which halved the area of  myo-
cardial infarct compared to iCORM control[74]. In a further 
study, the same group compared the effects of  CORM-3 
with a late-phase IPC protocol. Animals received either 
IPC or intravenous CORM-3 infusion lasting 60 min, with 
appropriate controls. Animals then underwent 30 min cor-
onary ischemic insults 24 to 120 h later. The reperfusion 
phase lasted for 24 h post-operatively before animals were 
killed and hearts examined for infarct size. Both IPC and 
CORM-3 infusion resulted in cardioprotection at between 
24 and 72 h compared with appropriate control groups[75].
In the context of  transplantation, the potential for 
using CO to enhance graft function has been explored 
in various transplantation models. In the kidney, several 
studies have successfully protected grafts using storage 
media supplemented with CORM-3/CORM-A1[76] or 
CORM-2[77] for extended periods of  cold ischemia prior 
to isogenic transplantation. In a vascular allograft model, 
donor HO-1 induction or CORM treatment reduced sub-
sequent CD8 influx and intimal hyperplasia lasting until 
animals were sacrificed at 6 wk[78].
In the liver, CO persufflation of  University of  Wis-
consin (UW) storage solution improved subsequent graft 
function[79], a result replicated using CORM-3 supple-
mented UW[80,81] after cold ischemic times of  48 h. Use of  
CO treatment in experimental liver transplant recipients 
has also been explored. Tomiyama et al[82] transplanted 
livers from wild-type donors into E-GFP transgenic rat 
recipients who received inhaled CO prior to and for the 
24 h post transplantation. Grafts within CO-treated re-
cipients were found to have reduced numbers of  infiltrat-
ing CD45+ host leucocytes, while purified donor CD68+ 
Kupffer cells produced less IL-6 and TNFα: primary 
cultured ex vivo Kupffer cells from CO-treated animals 
secreted less IL-6 and TNFα in response to lipopolysac-
charide (LPS) stimulus. 
CO clearly has powerful antioxidant and anti-inflam-
matory effects in a variety of  systems. For this reason, 
despite the difficulties presented by administering it in 
its inhaled form, phase 2 clinical trials are underway in 
renal transplantation (www.clinicaltrials.gov identifier 
NCT00531856), chronic obstructive pulmonary dis-
ease (NCT00094406) and post-operative intestinal ileus 
(NCT01050712). Further development of  CORMs should 
make CO therapies more convenient, thereby widening 
their potential clinical applications: on the basis of  the 
preclinical data presented above such applications would 
be expected to include hepatic IRI and transplantation.
Other mechanisms of HO-1-mediated cytoprotection
The bulk of  data exploring mechanisms of  HO-1-
induced cytoprotection supports the concept that it is its 
antioxidant function which protects cells and animals 
from injury. Two separate pieces of  data suggest that 
other mechanisms should be considered. Firstly, Ponka’s 
laboratory have demonstrated that the amounts of  intra-
cellular heme available for degradation may be insufficient 
to account for HO-1’s powerful antioxidant effects[61]. 
Secondly, Dennery’s laboratory has shown HO-1 translo-
cation to the nucleus after cellular hypoxia or heme treat-
ment, suggesting a role in transcriptional regulation[37]. 
Developing this work, this group has published research 
using a reporter system with catabolically inactive HO-1 
which suggests HO-1 may have a forward-acting positive 
effect upon its own transcription[83], although as yet there 
has been no work demonstrating a protective effect of  
catabolically inactive HO-1.
HO-1 AND IMMUNOMODULATION IN IRI
It is likely that HO-1 protects organs from IRI by modu-
lation of  both direct cellular injury and both the innate 
and adaptive immune systems[84]. Deficiency of  HO-1 in 
both humans and mice is associated with a pro-inflam-
matory phenotype[85,86]. 
According to Matzinger’s “Danger Model” of  the 
initiation of  immune responses to injured organs, injured 
parenchymal cells release “Danger-Associated Molecular 
Patterns” (DAMPs) which stimulate antigen presenting 
cell (APC) activation through pattern recognition recep-
tors[87,88]. Activated APCs subsequently activate and recruit 
immune effector cells through the secretion of  pro-in-
flammatory mediators (cytokines, chemokines and adhe-
sion molecules) and antigen presentation[9], resulting in 
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the activation and recruitment of  T cells and neutrophils 
(Figure 2). This recruitment of  leucocytes into the tissue 
is further facilitated by increased endothelial permeability 
and adhesion molecule expression resulting from endo-
thelial activation.
Danger-associated molecular patterns 
Hypoxic cellular injury can be regarded as the initiating 
event in a cascade of  immunological activation. “Danger-
Associated Molecular Patterns” or “alarmins” spilt by 
dying cells act on tissue resident immune populations via 
various molecular sensors including the toll-like receptor 
(TLR) family and purinergic receptors. A prototypic “alar-
min”, High Mobility Group Box-1 (HMGB1) is released 
passively from injured cells, a signal amplified by active 
secretion from surrounding viable immune and non-
immune cells[89]. Several authors have published studies 
demonstrating that circulating HMGB1 levels rise after 
experimental hepatic ischemia and that anti-HMGB1 
neutralizing antibodies are capable of  lowering circulat-
ing TNFα and IL-6 levels, and ameliorating injury[90-92]. 
Human clinical studies have confirmed the synthesis of  
HMGB1 during early reperfusion after liver transplanta-
tion, an effect exaggerated in steatotic livers, and with 
levels correlating with injury severity as measured by peak 
ALT[93]. Recombinant HMGB1 has been found to worsen 
the severity of  experimental hepatic ischemic injury, an 
effect neutralized by targeted deletion of  its receptor 
TLR-4[92]. 
HO-1 is capable of  modulating the HMGB1 alarmin 
system. In sepsis[94] and acute lung injury[95] models, mac-
rophage LPS-mediated HMGB1 release was suppressed 
by HO-1 induction by CORMs resulting in improved sur-
vival. Oxidative stress can initiate macrophage HMGB1 
synthesis which occurs in a dose response relationship 
with peroxide stress in vitro[96]. It is therefore unclear 
whether HO-1’s modulation of  HMGB1 secretion arises 
simply by reducing the extent of  parenchymal cell injury 
or whether it is dependant upon another mechanism. 
Free heme is another potential DAMP, being released 
from damaged cells and acting on TLRs[97]. Heme has 
also been shown to induce neutrophil chemotaxis using 
in vitro transmigration assays and after intraperitoneal in-
jection in vivo[98]. By metabolising free heme, HO-1 induc-
tion would be expected to reduce this immune stimulus, 
further contributing to the possible mechanisms of  pro-
tection from injury.
Intriguingly, HO-1 and CO also modulate TLR signal-
ing upon which many DAMPs converge[99]. CO treatment 
of  cultured RAW264.7 macrophages was found to reduce 
TLR4 signaling by reducing TLR4/Myd88 interactions 
and movement of  TLR4 receptors to the cell surface[100].
It is likely that much of  the immune modulation of-
fered by HO-1 is owed to its antioxidant action which 
quietens the initial immune stimulus by reducing cellular 
injury and spillage of  DAMPs. 
Kupffer cells
Hepatic tissue resident macrophages (Kupffer cells) are 
the first immune cells to be activated by IRI, being acted 
upon by DAMPs released from surrounding parenchymal 
cells as well as being subject themselves to cellular hy-
poxia. Subsequently, they coordinate an appropriate influx 
of  other immune cells by secretion of  chemokines and 
cytokines. Kupffer cells have the ability to harm surround-
ing parenchymal cells by secretion of  pro-inflammatory 
cytokines including TNFα, IL-6 and IL-1, which may be 
directly toxic[101]. On the other hand, Kupffer cells may 
protect the tissues by secretion of  anti-inflammatory cyto-
kines including IL-10. Furthermore, as the principle HO-
1-expressing cells of  the liver[24] they may secrete diffusible 
CO which may act in a paracrine manner upon surround-
ing cells to protect them from oxidative stress. 
In our work, we have identified that HO-1 acts as a 
powerful switch on resting macrophage differentiation. 
We found HO-1-deficient Kupffer cells in vivo and bone 
marrow-derived monocytes (BMDMs) in vitro to differen-
tiate down a Ly6c+ MARCO+ F4/80- pathway associated 
with macrophage inflammatory protein (MIP)-1 respon-
sive pro-inflammatory monocytes[102]. HO-1 deficiency 
was associated with marked susceptibility to hepatic IRI 
measured in terms of  ALT release and histological injury 
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score[24]. Parallel work elsewhere using an in vitro migration 
assay has demonstrated enhanced migration of  Hmox-1-/- 
BMDMs towards MIP-1α[95]. In an experimental liver 
transplant model, inhaled CO conferred protection from 
injury and reduced secretion of  pro-inflammatory cy-
tokines from recovered CD68+ cells cultured ex vivo[82], 
reducing the subsequent influx of  CD45+ leucocytes. 
In vitro and in vivo, low dose CO downregulates the pro-
duction of  macrophage pro-inflammatory cytokines 
[TNFα, IL1b and MIP-1b (CCL4)] and increases the ex-
pression of  the anti-inflammatory cytokine IL10[103].
Data from injury models showing modulation of  
pro-inflammatory cytokine secretion by HO-1 induction 
is subject to the criticism that the changes observed are 
merely the downstream effects of  parenchymal cellular 
protection, and suppression of  DAMPs. However, data 
from our laboratory has shown HO-1 effects upon the 
resting state of  macrophage differentiation implying that 
HO-1 may modulate immune responses themselves.
Adaptive immune system
There is growing evidence from a variety of  animal IRI 
models (T cell-deficient nude rats, severe combined im-
munodeficiency mice, RAG 1-/- mice, CD4+/CD8+-/- 
mice and CD4+ depleted mice) that there is a significant 
decrease in biochemical and histopathological evidence 
of  injury in the absence of  T cells (reviewed by Linfert 
et al[9]). More specifically, Khandoga et al[104] demonstrat-
ed it was a CD4+ rather than CD8+ T cell-dependent 
phenomenon; depletion of  CD4+ T cells leads to a sig-
nificant reduction in the observed injury. This influx of  
CD4+ cells on reperfusion is rapid and may determine 
the mode of  neutrophil activation and subsequently the 
extent of  the observed tissue damage[105,106]. In a series 
of  elegant adoptive transfer experiments with CD4+ 
cells in a renal model, Burne et al[107] found IRI to be an 
interferon-γ-dependent process; this may imply the im-
portance of  the T helper 1 lineage in the pathology of  
IRI. 
HO-1 has a number of  immunomodulatory effects on 
effector and Treg cells. HO-1 and CO appear to inhibit 
T cell proliferation and activation through the suppres-
sion of  IL-2 secretion[108]. HO-1 induction has also been 
shown to induce the apoptosis of  activated T helper cells 
through activation-induced cell death[109]. 
Treg cells suppress the activation of  the immune sys-
tem and inhibit the activation of  autoreactive T cells[110]. In 
clinical studies, Treg/Th17 “imbalance” has been associ-
ated with acute coronary syndromes[111]. HO-1 is induced 
by FoxP3: inhibition of  HO-1 function in vivo reduced 
the suppressive ability of  naturally occurring Tregs[112]. 
Furthermore, studies from Fritz Bach’s group have shown 
tolerogenesis to require HO-1[109]. Recently, however, these 
studies have been challenged by showing that Hmox-1-/- 
mice have normal numbers of  Treg cells[113] and that 
HO-1 is not necessary or sufficient for T reg function[114]. 
These controversies may be resolved by work from the 
Agarwal group which showed that although Hmox-1-/- 
mice had normal (or elevated) numbers of  circulating 
Treg cells, their suppressive function was dependant upon 
HO-1 expression by antigen-presenting cells[115].
In the context of  hepatic ischemia, further work is 
needed firstly to establish which T cell populations are 
responsible for IRI and IPC, and secondly to resolve the 
controversy concerning the role of  HO-1 in the expan-
sion of  different T cell subsets.
Neutrophils
Severe IRI is associated with significant influx of  neutro-
phils[9]. Their recruitment from the vascular compartment 
into the liver is mediated by the expression of  chemo-
kines, cytokines and adhesion molecules[9]. Accumulation 
of  activated neutrophils directly injures hepatocytes and 
the vascular epithelium through the release of  proteases 
and the generation of  ROS[116]. The initial recruitment of  
neutrophils appears to be a CD4+-dependent process[105]; 
continued neutrophil recruitment and activation may 
be dependent on the neutrophil production of  IL-17A, 
which is important in a positive feedback mechanism[117]. 
As described above, heme is also capable of  initiating 
neutrophil chemotaxis[98].
Although neutrophil influx is enhanced in Hmox-1-/- 
animals after ischemia-reperfusion insults[24], it is unclear 
whether this is due to a direct effect upon neutrophils or 
merely as a result of  reduced stimulation due to upstream 
effects.
CONCLUSION
A wealth of  data has now proven that HO-1, and its 
metabolites iron, bilirubin and CO, protect the liver from 
IRI. HO-1 appears to ameliorate ischemic injury through 
synergistic actions at many levels in the danger pathway. 
Powerful effects have been identified upon neutraliza-
tion of  OFR, and apparently at every step of  the ensuing 
danger pathway. What remains is to understand the true 
physiological importance of  each of  these effects, and to 
attempt to separate apparent immunomodulation from 
suppression of  upstream danger signals. Further under-
standing of  the detailed pathophysiology of  IRI and the 
mechanisms underlying IPC would also be invaluable in 
identifying the full range of  potential therapeutic targets. 
The protective effect of  HO-1 upregulation in IRI was 
first discovered over a decade ago, and is proven beyond 
doubt in preclinical studies. Work to date has highlighted 
multiple potential therapeutic strategies ranging from 
CORM infusions to cell therapies with HO-1-transduced 
macrophages. In light of  the severity of  the many clinical 
problems caused by IRI including the liver donor short-
age, there is now some urgency to translate this body of  
scientific knowledge into viable treatments which will 
benefit patients.
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